Form 4: Vertex Pharmaceuticals CEO Reshma Kewalramani Sells Shares Under 10b5-1 Trading Plan

Reshma Kewalramani, CEO of Vertex Pharmaceuticals, sold 15,202 shares of common stock at $447 per share on May 20, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On May 20, 2024, Reshma Kewalramani, the CEO and President of Vertex Pharmaceuticals, sold 15,202 shares of Vertex Pharmaceuticals' common stock.
• The sale was executed at a price of $447 per share.
• The transaction was conducted under a pre-arranged trading plan pursuant to Rule 10b5-1(c), which was established on February 7, 2024.
• Following the transaction, Kewalramani directly owns 121,374 shares of Vertex Pharmaceuticals' common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-arranged trading plan and doesn't necessarily indicate a positive or negative outlook on the company.

Industry Context

Sales by insiders are a common occurrence and are often pre-planned to avoid accusations of trading on inside information. The use of a 10b5-1 plan allows corporate insiders to sell shares at predetermined times and prices.

Stakeholder Impact

• The sale of shares by the CEO could have a minor impact on shareholder sentiment, but is unlikely to be significant given the pre-planned nature of the transaction.

Key Dates